PORTFOLIO

A weekly report compiled from the proxy statement and annual report of a publicly held company with local headquarters or a major division in the area

CVS/pharmacy°

New York Stock Exchange

Based in Woonsocket, R.I., CVS Caremark Corp. operates approximately 6,923 retail and specialty pharmacy stores in 41 states and the District of Columbia. In March 2007, CVS Corp. completed its merger with Caremark Rx Inc., creating CVS Caremark Corp. The company's operations are grouped into two businesses: retail pharmacy and pharmacy ser-The vices. The retail pharmacy business, through its drugstores, Web site and health clinic sells prescription drugs and an assortment of general merchandise. The pharmacy services segment provides a full range of prescription benefit management services to employers, insurance companies, unions, government employee groups, managed-care organizations and other sponsors of health benefit plans and individuals. CVS Caremark employs approx and other sponsors of health benefit plans and individuals. CVS Caremark employs approximately 211,000 people nationwide, including more than 26,000 pharmacists, nurse practitioners and physician assistants. The company operates 16 stores in Monroe County.

CVS Caremark reported net sales of \$98.7 billion during fiscal 2009, representing an increase of 12.9 percent over net sales of \$87.5 billion in 2008. Net income during 2009 in

creased 15.1 percent to \$3.7 billion, and net income per share increased 37 cents to \$2.55 per share. The company's annual dividend increased 5 cents to 31 cents per share. Net cash provided by operating activities was \$4.0 billion; net cash used in investing activities 1.1 billion; and net cash used in financing activities was \$3.2 billion.

The company's most recent fiscal year ended on Dec. 31, 2009.

Common shares outstanding as of March 29	1,388,453,000
Price per share of common stock on March 29	\$36.68
Total market value on March 29	\$50,928,456,040
Controlled by all directors and officers as a group	15,283,765 ¹
,	(1.1 percent)

Performance Record

(Dollars in millions except per-share data)						
•	2009	2008	2007	2006	2005	
Net sales	98,729	\$87,472	\$76,330	\$43,821	\$37,007	
Net income	3,696	3,212	2,637	1,369	1,223	
Net income per share	2.55	2.18	1.92	1.60	1.45	
Dividends per share	0.31	0.26	0.23	0.16	0.15	
Total assets	61,641	60,960	54,722	20,574	15,247	
Long-term debt	8,756	8,057	8,350	2,870	1,594	
Shareholders' equity	35,768	34,574	31,322	9,918	8,331	
Operating cash flow (loss)	4,035	3,947	3,230	1,742	1,612	
Investing cash flow (loss)	(1,069)	(4,581)	(3,082)	(4,593)	(912)	
Financing cash flow (loss)	(3,232)	929	378	2,868	(579)	

Directors Number of common shares¹

Management LLC 195 722 avid Brown II, 58, chairman, Broad and Cassel P.A.150.290 William Joyce, 74, chairman and chief executive officer,
Advanced Fusion Systems LLC136.031 Sheli Rosenberg, 68, adjunct professor, Northwestern University J.L. Kellogg Graduate School of Business .135,655 Jean-Pierre Millon, 59. 127.654 Marian Heard, 69, president and CEO, Oxen Hill Partners.....98,528 , non-executive chairman, Motorola Inc. ...91,412 David Dorman, 56 Terrence Murray, 70
Kristen Gibney Williams, 61
Richard Swift, 65

Executive Compensation


Officer 200	9 cash copensation ²
Thomas Ryan, chairman, president and CEO	\$36,479,788
Howard McLure, executive vice president, Caremark pharmacy service	es13,303,495
Larry Merlo, executive vice president,	
CVS pharmacy and retail	11,462,110
David Rickard, executive vice president, chief financial officer and	
chief administrative officer	10,971,562
Douglas Sgarro, executive vice president, chief legal officer	10,829,629
Troyen Bennan, executive vice president, chief medical officer	2,918,977
Above executive officers as a group	\$85 965 561

Includes shares that may be acquired through the exercise of stock options, shares granted under the company's incentive compensation plan or deferred stock compensation plans, and shares held in trusts

or partnerships

Includes salaries, value of stock and option awards, non-equity incentive plan compensation, change in pension value and nonqualified deferred compensation earnings, value realized from stock options exercised and all other compensation.

Stock Performance



.63,408 25,483